Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 2 5Phase 1 4Phase 1/2 3

Status

Recruiting 3Active not recruiting 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 5

Conditions

Breast Neoplasms 138Carcinoma, Non-Small-Cell Lung 109Prostatic Neoplasms 51Lung Neoplasms 31Neoplasm Metastasis 20Stomach Neoplasms 18Parkinson Disease 4, Autosomal Dominant Lewy Body 17Nasopharyngeal Carcinoma 16Neoplasms 15Squamous Cell Carcinoma of Head and Neck 14Esophageal Neoplasms 11Head and Neck Neoplasms 8Urinary Bladder Neoplasms 7HER2-positive Breast Cancer 7Esophageal Squamous Cell Carcinoma 7Ovarian Neoplasms 6Carcinoma 6Adenocarcinoma 6Inflammatory Breast Neoplasms 5Fallopian Tube Neoplasms 5Endometrial Neoplasms 5Carcinoma, Squamous Cell 5Adenocarcinoma of Lung 5Triple Negative Breast Neoplasms 4Recurrence 4Carcinoma, Transitional Cell 4Adenocarcinoma Of Esophagus 4Primary Breast Cancer 3Carcinoma, Ovarian Epithelial 3Adenocarcinoma, Bronchiolo-Alveolar 3

Interventions

Paclitaxel 25Doxorubicin 15Carboplatin 14pembrolizumab 10Cisplatin 8Radiotherapy 6Docetaxel 5Chemotherapy, Adjuvant 5Taxes 4Filgrastim 4Brachytherapy 4lenvatinib 3Observation 3trastuzumab deruxtecan 2selinexor 2olaparib 2durvalumab 2Tamoxifen 2Specimen Handling 2Ifosfamide 2Drug Therapy 2sintilimab 1sacituzumab govitecan 1pertuzumab 1nanocis 1liposomal doxorubicin 1ixabepilone 1gallium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1dostarlimab 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Endometrial Neoplasms × Docetaxel × Clear all
NCT06952504 2026-05-22

TroFuse-033

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,123 enrolled
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT06340568 2026-05-20

Fern-EC-01

BioNTech SE

Phase 3 Recruiting
480 enrolled
Gynecologic

Endometrial Neoplasms

NCT06989112 2026-05-06

DE-01

AstraZeneca

Phase 3 Recruiting
600 enrolled
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Neoplasms, Endometrial Neoplasms

NCT05173987 2026-05-05

KEYNOTE-C93

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
280 enrolled
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT04634877 2025-06-09

KEYNOTE-B21

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
990 enrolled
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡